To recover your password please fill in your email address
Please fill in below form to create an account with us
An international phase III randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer.
|
Trial Summary: |
The ICON8 trial is testing whether giving chemotherapy at the smaller dose more often is better than the traditional once every 3 weeks that has been the norm for many years. |
|
Supported By: |
MRC (UK) and Cancer Australia |
|
Eligibility: |
Women with newly diagnosed high-risk early stage or advanced stage epithelial, fallopian tube or primary peritoneal carcinoma, and ovarian carcinosarcoma. |
|
Registration ID: |
NCT01654146 |
|
Participation: |
International |
|
Australian Lead Group: |
ANZGOG |
|
Status: |
Closed |
|
Activation Date: |
27/11/2013 |
|
Chairs: |
Andrew Dean (Australia) |
|
Contact: |